Nebraska
Prescription drug spending and prescribing in Nebraska, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $1.6B for prescriptions written in Nebraska, the 38th most of 52 states and territories, and 3.4% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $1.6B
- Medicaid drugs, 2025: $504M
- Opioid share of claims: 3.4%
- Life-science raises, 2 years: $47M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Nebraska | United States | Difference |
|---|---|---|---|
| Opioids | 3.4% | 3.5% | -5% |
| Antibiotics | 4.1% | 4.4% | -8% |
| Antipsychotics | 2.0% | 1.7% | +14% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Nebraska's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Diphth,pertuss(Acell),tet Vac | 4.7× | 45,451 |
| Rsvpref3 Antigen/As01e/Pf | 4.4× | 80,425 |
| Varicella-Zoster Ge/As01b/Pf | 4.0× | 101,736 |
| Rsv Vacc, Pref A And Pref B/Pf | 2.5× | 26,067 |
| Pen Needle,dual Safety,diabetc | 2.5× | 6,019 |
| Vilazodone Hcl | 2.3× | 5,339 |
| Colestipol Hcl | 2.2× | 7,549 |
| Minocycline Hcl | 2.2× | 4,913 |
| Propafenone Hcl | 2.1× | 3,615 |
| Paliperidone | 2.1× | 5,340 |
Biggest Medicaid Drugs
What Nebraska's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
6 Form D raises by companies based in Nebraska in the last two years; the 10 largest. See all raises- Virtual Incision Corp$35M · Biotech · Oct 5, 2026
- Virtual Incision Corp$8M · Biotech · Apr 3, 2025
- Sower Solas I Sidecar III, LLC$4M · Biotech · Aug 12, 2025
- Centese, Inc.$525K · Other health care · May 12, 2025
- Empower Equity Group, LLC$100K · Other health care · Mar 12, 2025
- CAMcerta, INC$75K · Other health care · Mar 25, 2026
State Attorney General Health-Care Cases
Antitrust cases Nebraska joined, newest first; see every case- Plaintiff States and FTC v. CVET TOPCO, L.P. et al.2026 · Pending
- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- Maryland et al. v. Perrigo Company, No. 1:04CV01398 (D.D.C. Aug. 17, 2004)2004 · Settled
- Texas et al. v. Organon (Remeron), No. 04-5126 (D.N.J. 2004)2004 · Settled
- In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)2003 · Settled
- Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL…2002 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Virginia · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG